Blinatumomab (blincyto®) has achieved sequential regulatory milestones since its first accelerated approval in 2014 by the US Food and Drug Administration (FDA) for adult and pediatric (≧1month old) patients with relapsed or refractory CD19+ B-cell precursor acute lymphoblastic leukemia (ALL). This evidence concerns the gene CD19 and acute lymphoblastic leukemia.